

Galectin Therapeutics Inc. Investor Relations Department 4960 Peachtree Industrial Boulevard, Suite 240 Norcross, GA 30071 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

NASDAQ: GALT	
Last Trade:	2.36
Trade Time:	4:00 PM ET May 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.49 - 3.68
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

# Corporate Profile

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in... (more)

#### **Stock Performance**



## Press Releases [View all]

#### May 15, 2017

Galectin Therapeutics Reports 2017 First
Quarter Financial Results and Provides
Business Update

# May 3, 2017

Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease

#### Apr 25, 2017

Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

### Financials [View all]

First Quarter Financial Results

Mar 28, 2017 Annual Report (10-K)

Nov 10. 2016

Proxy Statement (DEF 14A)

May 15, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)